Search
Showing results for "8"
Research
The dual-pathway and cognitive-behavioural models of binge eating: prospective evaluation and comparisonThe aim of this study was to evaluate and compare the dual-pathway, original cognitive-behavioural, and enhanced "transdiagnostic" cognitive-behavioural...
Research
An eleven-year evaluation of the effect of community treatment orders on changes in mental health service useMany studies of compulsory community treatment have assessed their effect early on after the implementation of legislation.
Research
Vitamin D deficiency and the lung: Disease initiator or disease modifier?Vitamin D deficiency is a global public health problem and has been associated with an increased incidence and severity of many diseases including diseases...
Research
Bullying behaviour following students’ transition to a secondary boarding school contextThis study investigated the prevalence and types of bullying behaviour that boarding students experienced during the transition to a secondary boarding school.
Research
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), a 15-valent pneumococcal conjugate vaccine (PCV), when given to allo-HCT recipients.Â
Pneumococcal Vaccine Study
News & Events
Rethink needed on literacy interventionA new study by The Kids Research Institute Australia has found current early intervention programs are failing to identify a large proportion of children with language an
Research
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomabWe report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8).
Research
An evaluation of a data linkage training workshop for research ethics committeesIn Australia research projects proposing the use of linked data require approval by a Human Research Ethics Committee (HREC).